[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 609,122,176
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.24
  • Price/Sales 6.39
  • Price/Cash Flow 17.70
  • Price/Book 7.41

Options Overview Details

View History
  • Implied Volatility 26.05% (+1.81%)
  • Historical Volatility 28.89%
  • IV Percentile 85%
  • IV Rank 74.39%
  • IV High 30.74% on 07/07/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 4) 4.97 (2.00%)
  • Put/Call Vol Ratio 0.42
  • Today's Volume 22,420
  • Volume Avg (30-Day) 31,725
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 337,166
  • Open Int (30-Day) 371,868
  • Expected Range 243.85 to 253.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $3.04
  • Number of Estimates 6
  • High Estimate $3.14
  • Low Estimate $2.94
  • Prior Year $2.80
  • Growth Rate Est. (year over year) +8.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
227.50 +9.37%
on 06/22/26
269.43 -7.65%
on 07/07/26
+20.43 (+8.95%)
since 06/18/26
3-Month
220.37 +12.91%
on 05/11/26
269.43 -7.65%
on 07/07/26
+18.13 (+7.86%)
since 04/20/26
52-Week
162.78 +52.86%
on 07/21/25
269.43 -7.65%
on 07/07/26
+85.12 (+52.00%)
since 07/18/25

Most Recent Stories

More News
MarketBeat Week in Review – 07/13- 07/17

A tech selloff hit the S&P 500 and NASDAQ this week while energy and financial stocks gained; MarketBeat analysts recap Micron, Netflix, Broadcom, Apple and more ahead of Alphabet's earnings.

NFLX : 67.60 (-1.96%)
PYPL : 56.82 (+0.46%)
GOOGL : 351.99 (+1.51%)
META : 645.85 (-0.02%)
AAPL : 326.59 (-2.14%)
AVGO : 378.16 (+1.98%)
SNDK : 1,390.95 (+2.67%)
JNJ : 248.82 (-1.67%)
MU : 865.46 (+1.94%)
IONQ : 34.24 (-1.55%)
TSM : 402.30 (+0.99%)
SKHY : 151.16 (-1.86%)
Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

ATAI : 7.19 (-0.42%)
JNJ : 248.82 (-1.67%)
LLY : 1,146.90 (-2.73%)
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

New branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities. ...

JNJ : 248.82 (-1.67%)
DePuy Synthes Acquires Expanding Innovationsâ„¢

Transaction will bring expandable interbody cage solutions to DePuy Synthes' Spine portfolio to strengthen position across the lumbar fusion market

JNJ : 248.82 (-1.67%)
Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity

Johnson & Johnson's post-earnings pullback follows a revenue and EPS beat, raised guidance, and analyst price target increases, with talc litigation remaining the key risk to watch.

JNJ : 248.82 (-1.67%)
ISRG : 353.17 (+2.24%)
3 ETFs to Beat Back the Bears

The best time to know your options for a bear market is well before one happens. Here are three great ways to fend off a market downturn.

SPLV : 76.09 (-0.44%)
KO : 82.12 (+0.69%)
SH : 33.32 (+0.15%)
BNS : 87.06 (-2.65%)
JNJ : 248.82 (-1.67%)
PNW : 106.30 (-1.33%)
LVHI : 41.62 (-0.50%)
SHEL : 86.20 (-1.28%)
BHP : 80.49 (-0.19%)
FE : 48.54 (+0.02%)
3 Market-Beating Dividend Kings for Generations of Income

Three top-performing Dividend Kings combine decades of dividend growth with strong share-price gains and bullish analyst ratings.

MO : 74.66 (+0.61%)
JNJ : 248.82 (-1.67%)
NUE : 230.74 (-2.48%)
Nasdaq Futures Climb as ASML Fuels AI Optimism, U.S. PPI Data and Earnings in Focus

September Nasdaq 100 E-Mini futures (NQU26) are up +0.40% this morning as sentiment got a boost after ASML Holding’s earnings provided fresh evidence of unrelenting demand for cutting-edge chips.

BLK : 1,054.11 (-1.69%)
PYPL : 56.82 (+0.46%)
UAL : 117.52 (+1.83%)
AMAT : 525.70 (-0.75%)
CRWD : 198.49 (-2.26%)
SNDK : 1,390.95 (+2.67%)
AXFO.S.DX : 235.900 (+2.10%)
MS : 210.94 (-2.12%)
NQU26 : 28,987.50 (+0.73%)
JNJ : 248.82 (-1.67%)
ASML.NA : 1,520.800 (-1.05%)
OKTA : 148.41 (-0.63%)
Johnson & Johnson: Q2 Earnings Snapshot

Johnson & Johnson: Q2 Earnings Snapshot

JNJ : 248.82 (-1.67%)
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is...

JNJ : 248.82 (-1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 258.00
2nd Resistance Point 256.09
1st Resistance Point 252.45
Last Price 248.82
1st Support Level 246.91
2nd Support Level 245.00
3rd Support Level 241.36

See More

52-Week High 269.43
Last Price 248.82
Fibonacci 61.8% 228.69
Fibonacci 50% 216.10
Fibonacci 38.2% 203.52
52-Week Low 162.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.